Work

Previously treated advanced NSCLC cohort from a multi-disease phase 1 study of ramucirumab (R) plus pembrolizumab (P): Efficacy and safety data

Year: 2017

Type: article

Source: Annals of Oncology

DOI: 10.1093/annonc/mdx091.010

Authors: R.S. Herbst, J. Martin-Liberal, E. Calvo, N. Isambert, J. Bendell, P. Cassier, J. Jin, G. Mi, J. Rege, L. Paz-Ares

Institutions: Yale University, Vall d'Hebron Hospital Universitari, Centre Georges François Leclerc, Sarah Cannon, Tennessee Oncology, Centre Léon Bérard, Eli Lilly (United States), Hospital Universitario Virgen del Rocío

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2614072985

FWCI: 1.082

Cites:

Cited by: 13

Related to: 10